The future of anti-CD20 monoclonal antibodies: Are we making progress?

Waleed Alduaij, Tim M. Illidge

    Research output: Contribution to journalArticlepeer-review


    The anti-CD20 monoclonal antibody (mAb) rituximab has revolutionized the treatment of B-cell malignancies. This unprecedented success has not only substantially changed the mindset of the clinical community about the ability of mAb to improve outcomes but has catalyzed the interest in the pharmaceutical industry to develop the next generation of anti-CD20 mAbs. Since the introduction of rituximab 15 years ago, we have learned much about the potential mechanisms underlying the therapeutic efficacy of anti-CD20 mAbs. In parallel, many novel anti-CD20 mAbs have entered the clinic, each designed with modifications to structure aimed at further improving efficacy. On review of the newer generation of anti-CD20 mAbs entering clinical trials, it appears that the link between the novel mechanistic insights and the development of these next-generation anti-CD20 mAbs is unclear. As we move into an era of personalized medicine, it will become increasingly important for us to develop closer links between the emerging mechanistic insights and the clinical development, to further enhance the potency of anti-CD20 mAbs beyond that achieved with rituximab. © 2011 by The American Society of Hematology.
    Original languageEnglish
    Pages (from-to)2993-3001
    Number of pages8
    Issue number11
    Publication statusPublished - 17 Mar 2011


    Dive into the research topics of 'The future of anti-CD20 monoclonal antibodies: Are we making progress?'. Together they form a unique fingerprint.

    Cite this